2018
Tailored treatment of patients with hepatocellular carcinoma with portal vein invasion: experience from a multidisciplinary hepatobiliary tumor program within a NCI comprehensive cancer center
Walcott-Sapp S, Naugler S, Lim JY, Wagner J, Orloff SL, Farsad K, Kolbeck KJ, Kaufman J, Maynard E, Enestvedt CK, Mayo SC, Billingsley KG. Tailored treatment of patients with hepatocellular carcinoma with portal vein invasion: experience from a multidisciplinary hepatobiliary tumor program within a NCI comprehensive cancer center. Journal Of Gastrointestinal Oncology 2018, 9: 1074-1083. PMID: 30603126, PMCID: PMC6286927, DOI: 10.21037/jgo.2018.08.11.Peer-Reviewed Original ResearchPortal vein invasionLiver-directed therapiesIntra-arterial brachytherapyHepatocellular carcinomaTransarterial chemoembolizationVein invasionInitial HCC diagnosisLiver-directed treatmentsMean Child-TurcotteMedian alkaline phosphataseSupportive care groupLimited treatment optionsTreatment of patientsKaplan-Meier plotsComprehensive cancer centerLog-rank methodPalliative chemotherapyChild-TurcottePugh scoreLiver dysfunctionLiver involvementVenous involvementConsecutive patientsMost patientsOverall survival
2017
Colorectal Cancer Liver Metastasis: Evolving Paradigms and Future Directions
Zarour LR, Anand S, Billingsley KG, Bisson WH, Cercek A, Clarke MF, Coussens LM, Gast CE, Geltzeiler CB, Hansen L, Kelley KA, Lopez CD, Rana SR, Ruhl R, Tsikitis VL, Vaccaro GM, Wong MH, Mayo SC. Colorectal Cancer Liver Metastasis: Evolving Paradigms and Future Directions. Cellular And Molecular Gastroenterology And Hepatology 2017, 3: 163-173. PMID: 28275683, PMCID: PMC5331831, DOI: 10.1016/j.jcmgh.2017.01.006.Peer-Reviewed Original ResearchColorectal cancerHigh-risk patient cohortEarly detectionEffective prognostic indicatorTreatment of patientsTumor immune therapyNew therapeutic regimensColorectal tumor biologyCurative resectionIntrahepatic recurrenceRecurrent diseaseSystemic therapyTreatment toxicityLiver metastasesImmune therapyTreatment regimensPrognostic indicatorTherapeutic regimensCancer carePatient cohortMetastatic spreadTreatment responseHigh riskPrognostic studiesPatients
2008
Phase II trial of romidepsin (NSC-630176) in previously treated colorectal cancer patients with advanced disease: a Southwest Oncology Group study (S0336)
Whitehead R, Rankin C, Hoff P, Gold P, Billingsley K, Chapman R, Wong L, Ward J, Abbruzzese J, Blanke C. Phase II trial of romidepsin (NSC-630176) in previously treated colorectal cancer patients with advanced disease: a Southwest Oncology Group study (S0336). Investigational New Drugs 2008, 27: 469. PMID: 18941712, PMCID: PMC3024913, DOI: 10.1007/s10637-008-9190-8.Peer-Reviewed Original ResearchConceptsMetastatic colorectal cancerColorectal cancerPerformance statusSouthwest Oncology Group studyAdequate bone marrowCombination of romidepsinPrior chemotherapy regimenPrior chemotherapy regimensSignificant cardiac diseaseHuman tumor xenograft modelsAdvanced colorectal cancerPhase II trialColorectal cancer patientsGroup of patientsTreatment of patientsTumor growth inhibitionTumor xenograft modelHistone deacetylase inhibitorsEligible patientsPrior chemotherapyPrior regimensStable diseaseAdvanced diseaseChemotherapy regimenChemotherapy regimens